These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25572120)

  • 21. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer.
    Akada M; Crnogorac-Jurcevic T; Lattimore S; Mahon P; Lopes R; Sunamura M; Matsuno S; Lemoine NR
    Clin Cancer Res; 2005 Apr; 11(8):3094-101. PubMed ID: 15837765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maspin mediates the gemcitabine sensitivity of hormone-independent prostate cancer.
    Huang CY; Chang YJ; Luo SD; Uyanga B; Lin FY; Tai CJ; Huang MT
    Tumour Biol; 2016 Mar; 37(3):4075-82. PubMed ID: 26490978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway.
    Yao J; Qian C
    Med Oncol; 2010 Sep; 27(3):1017-22. PubMed ID: 19816816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Downregulation of the nucleosome-binding protein 1 (NSBP1) gene can inhibit the in vitro and in vivo proliferation of prostate cancer cells.
    Jiang N; Zhou LQ; Zhang XY
    Asian J Androl; 2010 Sep; 12(5):709-17. PubMed ID: 20531280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HMGN5 expression in bladder cancer tissue and its role on prognosis.
    Wu J; Wang J
    Eur Rev Med Pharmacol Sci; 2018 Feb; 22(4):970-975. PubMed ID: 29509244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HMGN5 promotes IL-6-induced epithelial-mesenchymal transition of bladder cancer by interacting with Hsp27.
    Yao K; He L; Gan Y; Liu J; Tang J; Long Z; Tan J
    Aging (Albany NY); 2020 Apr; 12(8):7282-7298. PubMed ID: 32315283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer.
    Wang Y; Kuramitsu Y; Tokuda K; Baron B; Kitagawa T; Akada J; Maehara S; Maehara Y; Nakamura K
    PLoS One; 2014; 9(10):e109076. PubMed ID: 25271986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of microRNA-495 suppresses the proliferation and invasion and induces the apoptosis of osteosarcoma cells by targeting high-mobility group nucleosome-binding domain 5.
    Jiang W; Zheng J; Yu T; Wang J
    Oncol Rep; 2017 Aug; 38(2):1099-1107. PubMed ID: 28627703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.
    Wu ZH; Lin C; Liu MM; Zhang J; Tao ZH; Hu XC
    PLoS One; 2016; 11(12):e0169230. PubMed ID: 28036386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mechanism of SPARC-enhanced chemosensitivity of pancreatic cancer cells to gemcitabine].
    Zhang J; Jiang H; Mao Z; Wang X; Fan X; Liu Y; Wang Y
    Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):335-40. PubMed ID: 25030587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphorylation status of heat shock protein 27 plays a key role in gemcitabine-induced apoptosis of pancreatic cancer cells.
    Nakashima M; Adachi S; Yasuda I; Yamauchi T; Kawaguchi J; Itani M; Yoshioka T; Matsushima-Nishiwaki R; Hirose Y; Kozawa O; Moriwaki H
    Cancer Lett; 2011 Dec; 313(2):218-25. PubMed ID: 21999932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines.
    Zhang HH; Zhang ZY; Che CL; Mei YF; Shi YZ
    Int J Clin Exp Pathol; 2013; 6(9):1734-46. PubMed ID: 24040438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.
    Jacob DA; Bahra M; Langrehr JM; Boas-Knoop S; Stefaniak R; Davis J; Schumacher G; Lippert S; Neumann UP
    J Gastroenterol Hepatol; 2007 May; 22(5):738-48. PubMed ID: 17444865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
    Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
    Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
    Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
    Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
    Liu F; Gore AJ; Wilson JL; Korc M
    PLoS One; 2014; 9(1):e84982. PubMed ID: 24409315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine.
    Kawahara T; Aljarah AK; Shareef HK; Inoue S; Ide H; Patterson JD; Kashiwagi E; Han B; Li Y; Zheng Y; Miyamoto H
    Prostate; 2016 Jun; 76(8):744-56. PubMed ID: 26864615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
    Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
    J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
    Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
    Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
    Skrypek N; Vasseur R; Vincent A; Duchêne B; Van Seuningen I; Jonckheere N
    Oncotarget; 2015 May; 6(13):10853-67. PubMed ID: 25890497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.